 |
|
Long-term Assessment of Psychological Well-being in a Randomized Placebo-Controlled Trial of Cholesterol Reduction With Pravastatin
Ralph A. Stewart, MD, FRACP;
Katrina J. Sharples, PhD;
Fiona M. North, PhD;
David B. Menkes, MB, BS, FRANZCP;
Jenny Baker, MB, BS, FRACMA, FAFPHM;
John Simes, MD, FRACP;
for the LIPID Study Investigators
Arch Intern Med. 2000;160:3144-3152.
Background There is controversial evidence that a low serum cholesterol level is associated with an increased risk of depression, suicide, and violence. The aim of this study was to identify or exclude any small or infrequent adverse effect of long-term reduction of serum cholesterol with pravastatin sodium on psychological well-being.
Methods The study population consisted of 1130 respondents from a representative sample of 1222 patients with stable coronary artery disease participating in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study. Subjects were randomized in a double-blind manner to treatment with pravastatin sodium, 40 mg/d (n = 559), or placebo (n = 571) for at least 4 years. Psychological well-being was assessed with a standard self-administered questionnaire at baseline and after 6 months, 1 year, 2 years, and 4 years. The questionnaire assessed anxiety and depression, anger, impulsiveness, alcohol consumption, and adverse life events.
Results Serum cholesterol levels decreased by an average of 1.3 mmol/L (50 mg/dL) with pravastatin therapy and did not change with placebo. During follow-up there was no significant difference by treatment group in measures of anxiety and depression, anger expression, or impulsiveness (95% confidence interval excluded differences of >0.2 SD) and no difference in the proportion of subjects with excessive alcohol consumption or adverse life events (odds ratio, 1.0; 95% confidence interval, 0.8-1.2). There was no evidence of a treatment effect for persons whose baseline serum cholesterol level was in the lowest 10% (<4.6 mmol/L [178 mg/dL]) or whose scores for anxiety and depression, anger, or impulsiveness were in the highest 10% at baseline. There was no association between change in the serum cholesterol level and measures of anxiety and depression, anger, or impulsiveness during follow-up.
Conclusion Long-term reduction of serum cholesterol with pravastatin has no adverse effect on psychological well-being.
From the Departments of Medicine (Dr Stewart), Preventive and Social Medicine (Drs Sharples and North), and Psychiatry (Dr Menkes), University of Otago, Dunedin, New Zealand; and National Health and Medical Research Council Clinical Trials Centre, Sydney, Australia (Drs Baker and Simes).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Characterization of the Lipid Profile in Dementia and Depression in the Elderly
Dimopoulos et al.
J Geriatr Psychiatry Neurol 2007;20:138-144.
ABSTRACT
Lipids and essential fatty acids in patients presenting with self-harm
GARLAND et al.
Br. J. Psychiatry 2007;190:112-117.
ABSTRACT
| FULL TEXT
Probable need for psychiatric treatment is not the same as depression
Frasure-Smith et al.
Eur Heart J 2004;25:994-995.
FULL TEXT
Bias in the evaluation of evidence linking depression to cardiovascular mortality: reply
Stewart et al.
Eur Heart J 2004;25:995-995.
FULL TEXT
Depression and cardiovascular morbidity and mortality: cause or consequence?
Stewart et al.
Eur Heart J 2003;24:2027-2037.
ABSTRACT
| FULL TEXT
Long-term statin use and psychological well-being
Young-Xu et al.
J Am Coll Cardiol 2003;42:690-697.
ABSTRACT
| FULL TEXT
Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies
Kreisberg and Oberman
J. Clin. Endocrinol. Metab. 2002;87:423-437.
FULL TEXT
|
